Skip to content

Cognitive Rehabilitation Therapy for Mild Cognitive Impairment

Cognitive Rehabilitation for Older Veterans With Mild Cognitive Impairment

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03225482
Enrollment
193
Registered
2017-07-21
Start date
2018-07-11
Completion date
2024-06-30
Last updated
2025-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Keywords

Mild Cognitive Impairment, Cognitive rehabilitation, Cognitive training, Cognitive remediation

Brief summary

The number of older Veterans with Mild Cognitive Impairment (MCI) seeking care within the Veterans Affairs (VA) health care system is increasing and is expected to increase more rapidly as Vietnam era Veterans age. The cognitive effects of MCI and subsequent neurodegenerative disorders can adversely affect a Veteran's ability to function independently and failure to provide appropriate intervention can result in an increased need for healthcare services and VA benefits in the future. The VA currently spends over $19,000 annually per patient to care for Veterans with dementia (Zhu et al., 2009), and delaying the onset of dementia even by one to two years will result in substantial financial savings to the VA and quality of life gains for the Veteran. Since present pharmacological interventions have demonstrated limited efficacy, alternative treatments are needed. Therefore, an evidence-based cognitive training intervention that optimally addresses the needs of older Veterans with MCI is of critical importance to the VA patient care mission.

Detailed description

Due to the aging of the United States population, age-related cognitive problems resulting from Alzheimer's disease and other causes of dementia are increasingly prevalent. Before individuals are diagnosed with dementia, they typically exhibit a period of mild cognitive impairment (MCI). Mild cognitive problems associated with MCI frequently impact an individual's ability to perform everyday tasks, including working, independent living, and medication adherence. Veterans are at increased risk of cognitive decline, and the Veterans Healthcare Administration (VA) is now providing health care to surging numbers of older Veterans with MCI who report significant cognitive complaints, difficulties with everyday functioning, and concerns about impending dementia. Despite high patient demand, few cognitive rehabilitation interventions exist that specifically address the needs of older Veterans with MCI that are widely accessible, patient-centered, and evidence-based. To the investigators' knowledge, no randomized controlled trials have been conducted that evaluate the efficacy of manualized, brief and inexpensive, yet comprehensive (multi-modal) cognitive rehabilitation interventions for older Veterans with MCI. Hence, the primary objective of this study is to evaluate the efficacy of Motivationally Enhanced Compensatory Cognitive Training (ME-CCT), a manualized cognitive rehabilitation group treatment for older Veterans with MCI. The study's specific aims are to determine whether ME-CCT is effective for: 1) improving objective cognitive performance and functional capacity, 2) improving subjective cognitive complaints, subjective functioning, and collateral measures of everyday function, and 3) increasing modifiable protective factors (e.g., diet, exercise) associated with reduced risk for MCI. The investigators will also explore mediators and moderators of treatment effects. The overall goal is to evaluate a manualized group treatment for the symptoms of MCI that can be readily implemented in VA treatment settings. The study design makes use of the convergent availability of resources at the two participating VA Healthcare Systems in San Diego, California and Portland, Oregon to conduct a randomized controlled trial of ME-CCT. The study will recruit a sample of 216 Veterans (108 at each site) who meet criteria for MCI. Inclusion criteria will be: 1) Veterans 55 years old or older enrolled at one of the participating VAs who are able to provide informed consent, 2) Independently living, 3) Meet criteria for MCI based on previously published criteria (Petersen, 2004; Petersen, 2011), and 4) Willingness to participate in audio-recorded group sessions. Exclusion criteria will be: 1) Current substance use disorder with less than 30 days abstinence, 2) History of schizophrenia, schizoaffective disorder, or other primary psychotic disorder, 3) History of significant head trauma with loss of consciousness \>30 minutes, and 4) Auditory or visual impairments that would prevent ability to participate in the cognitive rehabilitation group. Eligible participants will be randomly assigned to either the ME-CCT or an active control group, Goal-focused Supportive Contact (SC). The SC group will provide the same frequency and amount of therapist and peer contact as ME-CCT, but without specific training in cognitive strategies, lifestyle strategies, or motivational enhancement. 8 2-hour long weekly sessions will be delivered in both conditions. Both groups will undergo evaluations at baseline, 4 weeks (midway through the intervention), 8 weeks (immediately following the end of the intervention), and 21 weeks (3 months after completion of the intervention).

Interventions

BEHAVIORALMotivationally Enhanced Compensatory Cognitive Training

ME-CCT is a manualized group-based behavioral intervention (8 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.

SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.

Sponsors

Portland VA Medical Center
CollaboratorFED
VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Outcomes assessors will be blind to treatment group assignment.

Intervention model description

Two group randomized controlled trial.

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Veterans \>55 years old enrolled at one of the participating VA sites (VASDHS and VAPORHCS) who are able to provide informed consent * Independently living * Meet criteria for MCI based on previously published criteria (see below) * Willingness to participate in audio-recorded sessions. * MCI Criteria: * Concern about a decline in cognitive functioning expressed by a physician, informant, participant or nurse * Cognitive impairment in one or more of the following domains * executive function * memory * attention * language or visuospatial abilities * Normal or minimal impairment in functional activities * Does not meet criteria for dementia

Exclusion criteria

* Current substance use disorder with \< 30 days abstinence * History of schizophrenia, schizoaffective disorder, or other primary psychotic disorder * History of significant brain injury with loss of consciousness \> 30 minutes * Auditory or visual impairments that would prevent ability to participate in the cognitive rehabilitation group or benefit from compensatory strategies

Design outcomes

Primary

MeasureTime frameDescription
Change in Objective Cognitive Performance Composite z Scoreassessed at baseline, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.Change in composite z score on the following tests: Hopkins Verbal Learning Test-Revised (HVLT-R) Brief Visuospatial Memory Test-Revised (BVMT-R) Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV) Digit Span WAIS-IV Coding Delis-Kaplan Executive Function System (D-KEFS) Trails, Number and Letter Sequencing D-KEFS Trails, Number-Letter Switching D-KEFS Color-Word Interference Test, Inhibition and Inhibition-Switching A Z score of 0 represents the sample mean. Higher composite Z scores reflect better performance.
Change in Functional Capacity Performance Composite z Scoreassessed at baseline, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.Change in composite z score on the following measures: UCSD Performance-Based Skills Assessment-Brief (UPSA-B) Medication Management Ability Assessment (MMAA) Neuropsychological Assessment Battery Daily Living Memory Neuropsychological Assessment Battery Judgment Neuropsychological Assessment Battery Driving Scenes A Z score of 0 represents the sample mean. Higher Z scores reflect better performance.

Secondary

MeasureTime frameDescription
Change in Cognitive Activity Inventoryassessed at baseline, 4 weeks, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.Change in total score on the Cognitive Activity Inventory. Scores represent hours per month of cognitive activity and range from 0-730 (the number of hours in a month). Higher scores represent more hours of cognitive activity.
Change in CHAMPS Physical Activity Questionnaire for Older Adultsassessed at baseline, 4 weeks, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.Change in total score on the CHAMPS Physical Activity Questionnaire for Older Adults. The score reflects hours of exercise per week and ranges from 0-168 (the number of hours in one week). Higher scores reflect higher levels of exercise.
Change in Subjective Everyday Functioning Composite Scoreassessed at baseline, 4 weeks, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.Change in average total score across Applied Cognition Executive Function and Applied Cognition General Concerns scales. The average total score ranges from 8-40, with higher scores reflecting better subjective cognition.
Change in Fitbit-measured Physical Activity Levelassessed at baseline, 1, 2, 3, 4, 5, 6, 7, 8, 21 weeks; change from baseline to 21 weeks reported.Change in total daily step count as measured by Fitbit. Scores could range from 0 steps per day to over 20,000 steps per day. Higher scores reflect more steps per day.
Change in Fitbit-measured Sleep Timeassessed at baseline, 1, 2, 3, 4, 5, 6, 7, 8, 21 weeks; change from baseline to 21 weeks reported.Change in total sleep time in minutes, per 24 hours, as measured by Fitbit. Possible scores range from 0-1440 (the number of minutes in 24 hours). Higher scores reflect more minutes of sleep.
Change in Portland Cognitive Strategies Scaleassessed at baseline, 4 weeks, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.Change in total score on the Portland Cognitive Strategies Scale. Scores reflect use of cognitive strategies and range from 0-60, with higher scores reflecting greater use of cognitive strategies.
Change in Everyday Cognition Scaleassessed at baseline, 4 weeks, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.Change in total score on the Everyday Cognition Scale. Total scores range from 39-195, with higher scores reflecting worse everyday cognition.

Countries

United States

Participant flow

Pre-assignment details

Participants were considered enrolled when they signed the informed consent form. Participants then underwent baseline assessment. Once six participants completed baseline assessments, they were randomized as a group to a condition, revealed to them on the first day of treatment. Some participants exited prior to baseline assessment or after baseline assessment but before randomization or the first day of treatment. Thus, the number initiating treatment differs from the number enrolled.

Participants by arm

ArmCount
ME-CCT
8-week Motivationally Enhanced Compensatory Cognitive Training group
84
Supportive Contact Control Group
8-week Goal-focused Supportive Contact group
72
Total156

Baseline characteristics

CharacteristicSupportive Contact Control GroupTotalME-CCT
Age, Continuous71.8 year
STANDARD_DEVIATION 7
71.5 year
STANDARD_DEVIATION 7.6
71.2 year
STANDARD_DEVIATION 8.2
Ethnicity (NIH/OMB)
Hispanic or Latino
6 Participants11 Participants5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
57 Participants123 Participants66 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
9 Participants22 Participants13 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Asian
1 Participants5 Participants4 Participants
Race (NIH/OMB)
Black or African American
4 Participants14 Participants10 Participants
Race (NIH/OMB)
More than one race
4 Participants10 Participants6 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants5 Participants2 Participants
Race (NIH/OMB)
White
60 Participants120 Participants60 Participants
Sex: Female, Male
Female
7 Participants19 Participants12 Participants
Sex: Female, Male
Male
65 Participants137 Participants72 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 790 / 66
other
Total, other adverse events
0 / 790 / 66
serious
Total, serious adverse events
3 / 793 / 66

Outcome results

Primary

Change in Functional Capacity Performance Composite z Score

Change in composite z score on the following measures: UCSD Performance-Based Skills Assessment-Brief (UPSA-B) Medication Management Ability Assessment (MMAA) Neuropsychological Assessment Battery Daily Living Memory Neuropsychological Assessment Battery Judgment Neuropsychological Assessment Battery Driving Scenes A Z score of 0 represents the sample mean. Higher Z scores reflect better performance.

Time frame: assessed at baseline, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.

Population: 111 participants had useable data at baseline and 21 weeks.

ArmMeasureValue (MEAN)Dispersion
ME-CCTChange in Functional Capacity Performance Composite z Score.11 z-scoreStandard Deviation 0.41
Supportive Contact Control GroupChange in Functional Capacity Performance Composite z Score.17 z-scoreStandard Deviation 0.61
Primary

Change in Objective Cognitive Performance Composite z Score

Change in composite z score on the following tests: Hopkins Verbal Learning Test-Revised (HVLT-R) Brief Visuospatial Memory Test-Revised (BVMT-R) Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV) Digit Span WAIS-IV Coding Delis-Kaplan Executive Function System (D-KEFS) Trails, Number and Letter Sequencing D-KEFS Trails, Number-Letter Switching D-KEFS Color-Word Interference Test, Inhibition and Inhibition-Switching A Z score of 0 represents the sample mean. Higher composite Z scores reflect better performance.

Time frame: assessed at baseline, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.

Population: 114 participants had useable data at baseline and 21 weeks.

ArmMeasureValue (MEAN)Dispersion
ME-CCTChange in Objective Cognitive Performance Composite z Score.24 Z scoreStandard Deviation 0.39
Supportive Contact Control GroupChange in Objective Cognitive Performance Composite z Score.14 Z scoreStandard Deviation 0.35
Secondary

Change in CHAMPS Physical Activity Questionnaire for Older Adults

Change in total score on the CHAMPS Physical Activity Questionnaire for Older Adults. The score reflects hours of exercise per week and ranges from 0-168 (the number of hours in one week). Higher scores reflect higher levels of exercise.

Time frame: assessed at baseline, 4 weeks, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.

Population: 116 participants had useable data at baseline and 21 weeks.

ArmMeasureValue (MEAN)Dispersion
ME-CCTChange in CHAMPS Physical Activity Questionnaire for Older Adults-2.02 hoursStandard Deviation 9.15
Supportive Contact Control GroupChange in CHAMPS Physical Activity Questionnaire for Older Adults1.76 hoursStandard Deviation 9.8
Secondary

Change in Cognitive Activity Inventory

Change in total score on the Cognitive Activity Inventory. Scores represent hours per month of cognitive activity and range from 0-730 (the number of hours in a month). Higher scores represent more hours of cognitive activity.

Time frame: assessed at baseline, 4 weeks, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.

Population: 120 participants had useable data at baseline and 21 weeks.

ArmMeasureValue (MEAN)Dispersion
ME-CCTChange in Cognitive Activity Inventory24.37 hoursStandard Deviation 245.46
Supportive Contact Control GroupChange in Cognitive Activity Inventory-26.80 hoursStandard Deviation 288.83
Secondary

Change in Everyday Cognition Scale

Change in total score on the Everyday Cognition Scale. Total scores range from 39-195, with higher scores reflecting worse everyday cognition.

Time frame: assessed at baseline, 4 weeks, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.

Population: 122 participants had useable data at baseline and 21 weeks.

ArmMeasureValue (MEAN)Dispersion
ME-CCTChange in Everyday Cognition Scale-.32 score on a scaleStandard Deviation 0.55
Supportive Contact Control GroupChange in Everyday Cognition Scale-.10 score on a scaleStandard Deviation 0.41
Secondary

Change in Fitbit-measured Physical Activity Level

Change in total daily step count as measured by Fitbit. Scores could range from 0 steps per day to over 20,000 steps per day. Higher scores reflect more steps per day.

Time frame: assessed at baseline, 1, 2, 3, 4, 5, 6, 7, 8, 21 weeks; change from baseline to 21 weeks reported.

Population: 31 participants had useable data at baseline and 21 weeks. Fitbits were only added at the San Diego site.

ArmMeasureValue (MEAN)Dispersion
ME-CCTChange in Fitbit-measured Physical Activity Level146.62 stepsStandard Deviation 1962.36
Supportive Contact Control GroupChange in Fitbit-measured Physical Activity Level-867.84 stepsStandard Deviation 1198.58
Secondary

Change in Fitbit-measured Sleep Time

Change in total sleep time in minutes, per 24 hours, as measured by Fitbit. Possible scores range from 0-1440 (the number of minutes in 24 hours). Higher scores reflect more minutes of sleep.

Time frame: assessed at baseline, 1, 2, 3, 4, 5, 6, 7, 8, 21 weeks; change from baseline to 21 weeks reported.

Population: 25 participants had useable data at baseline and 21 weeks. Fitbits were only used at the San Diego site.

ArmMeasureValue (MEAN)Dispersion
ME-CCTChange in Fitbit-measured Sleep Time-25.63 minutesStandard Deviation 90.29
Supportive Contact Control GroupChange in Fitbit-measured Sleep Time11.57 minutesStandard Deviation 64.73
Secondary

Change in Portland Cognitive Strategies Scale

Change in total score on the Portland Cognitive Strategies Scale. Scores reflect use of cognitive strategies and range from 0-60, with higher scores reflecting greater use of cognitive strategies.

Time frame: assessed at baseline, 4 weeks, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.

Population: 119 participants had useable data at baseline and 21 weeks.

ArmMeasureValue (MEAN)Dispersion
ME-CCTChange in Portland Cognitive Strategies Scale4.28 score on a scaleStandard Deviation 8.13
Supportive Contact Control GroupChange in Portland Cognitive Strategies Scale1.65 score on a scaleStandard Deviation 7.03
Secondary

Change in Subjective Everyday Functioning Composite Score

Change in average total score across Applied Cognition Executive Function and Applied Cognition General Concerns scales. The average total score ranges from 8-40, with higher scores reflecting better subjective cognition.

Time frame: assessed at baseline, 4 weeks, 8 weeks, 21 weeks; change from baseline to 21 weeks reported.

Population: 121 participants had useable data at baseline and 21 weeks.

ArmMeasureValue (MEAN)Dispersion
ME-CCTChange in Subjective Everyday Functioning Composite Score2.41 score on a scaleStandard Deviation 4.76
Supportive Contact Control GroupChange in Subjective Everyday Functioning Composite Score.64 score on a scaleStandard Deviation 4.46

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026